Benjamin J. Samelson‐Jones

Hemophilia B Gene Therapy with a High-Specific-Activity Factor IX Variant

Lindsey A. George, Spencer K. Sullivan, Adam Giermasz et al. · New England Journal of Medicine · 2017 · 759 citations · Full text

Medicine, Hematology, Molecular Medicine +15

Multiyear Factor VIII Expression after AAV Gene Transfer for Hemophilia A

Lindsey A. George, Paul E. Monahan, M. Elaine Eyster et al. · New England Journal of Medicine · 2021 · 253 citations · Full text

Medicine, Hematology, Molecular Medicine +13

Long-Term Follow-Up of the First in Human Intravascular Delivery of AAV for Gene Transfer: AAV2-hFIX16 for Severe Hemophilia B

Lindsey A. George, Margaret V. Ragni, John E.J. Rasko et al. · Molecular Therapy · 2020 · 209 citations · Full text

Medicine, Hematology, Immunology +13

Timing of Intensive Immunosuppression Impacts Risk of Transgene Antibodies after AAV Gene Therapy in Nonhuman Primates

Benjamin J. Samelson‐Jones, Jonathan D. Finn, Patricia Favaro et al. · Molecular Therapy — Methods & Clinical Development · 2020 · 48 citations · Full text

Life Sciences, Immunology, Molecular Medicine +17

Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity

Benjamin J. Samelson‐Jones, Jonathan D. Finn, Lindsey A. George et al. · JCI Insight · 2019 · 45 citations · Full text

Medicine, Hematology, Molecular Biology +16